About Porton Pharma Solutions Company

The company was founded in 2005 and is an internationally leading pharmaceutical contract customized R&D and manufacturing enterprise (CDMO). It was listed on the Shenzhen Stock Exchange in 2014 (stock code: 300363). The company mainly provides customized R&D and production services for chemicals (including starting materials, intermediates, APIs, formulations) and biopharmaceuticals (including plasmids, viral vectors, cell therapy, gene therapy) required for the entire life cycle from early clinical research to drug marketing. The main business can be divided into: small molecule API CDMO business, small molecule formulation CDMO business, gene cell therapy CDMO business, synthetic macromolecule CDMO business. During the reporting period for chemical raw material CDMO business (including intermediates), chemical formulation CDMO business, and biological CDMO business (including gene therapy and cell therapy), the company won titles such as “2022 Chongqing Top 100 Private Enterprises”, “Chongqing Digital Workshop”, “Chongqing Innovation Demonstration Smart Factory”, “Excellent Practice Case of Listed Company's 2021 Performance Briefing Conference”, and “2022 Extraordinary Employer Award”. The subsidiary Jiangxi Boteng won the “2022 Advanced Grassroots Party Organization” and “2021 Advanced Green Development Advanced Enterprise” ”, “2021 Top Ten Tax Contributing Companies”; the subsidiary Boteng Biotech won titles such as “2022 Most Promising Employer” and “2022 Top 10 Most Growing CXO Companies”.